Global Psoriatic Arthritis Treatment Market 2024 , Forecast To 2033
7 Mar, 2024
The psoriatic arthritis treatment market has shown strong growth recently, with its size increasing from $10.93 billion in 2023 to $12 billion in 2024, marking a compound annual growth rate (CAGR) of 9.8%. This growth can be attributed to factors such as increased diagnosis and rising awareness of psoriatic arthritis treatments. Looking ahead, the market is expected to continue its strong growth, reaching $17.16 billion in 2028 at a CAGR of 9.4%. Factors contributing to this growth may include personalized medicine and emerging biologics. Major trends in this period could include advancements in biologics and patient-centered care.
Global Psoriatic Arthritis Treatment Market Key Driver
The rise in the prevalence of psoriasis and psoriatic arthritis boosted the growth of the psoriatic arthritis treatment market (33). Psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life (34). For instance, in June 2021, according to the National Psoriasis Foundation, a US-based healthcare agency, more than 8 million people in the United States and 125 million people worldwide suffered from psoriasis, a chronic immune-mediated illness (35). Furthermore, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis (36). Thus, an increase in the prevalence of psoriasis and psoriatic arthritis drives market growth (37).
Get A Free Sample Of The Global Psoriatic Arthritis Treatment Market ReportGlobal Psoriatic Arthritis Treatment Market Segments
The psoriatic arthritis treatment market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the psoriatic arthritis treatment market in 2023. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Psoriatic Arthritis Treatment Industry Players
AbbVie Inc.; Amgen Astellas BioPharma K.K.; Johnson & Johnson Services Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer Inc.; CB Biosciences Inc.; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AstraZeneca plc; Sanofi SA; Otsuka Pharmaceutical Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Bayer AG; Abbott Laboratories; Eisai Inc.; Janssen Pharmaceuticals Inc.; Bausch Health Companies Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences Inc.; GlaxoSmithKline plc; LEO Pharma A/S; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Valeant Pharmaceuticals International Inc.; Chugai Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.
Get The Full Global Psoriatic Arthritis Treatment Market ReportPsoriatic Arthritis Treatment Market Overview
Psoriatic arthritis treatment refers to a method of treatment or drug used to stop or lessen a chronic inflammatory disease of the joints and the areas where tendons and ligaments attach to the bones (entheses). This treatment focuses on controlling skin involvement and treating joint pain and disability.